|Bid||10.24 x 1200|
|Ask||10.25 x 1800|
|Day's Range||10.22 - 10.35|
|52 Week Range||9.90 - 11.29|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BALA CYNWYD, PA / ACCESSWIRE / May 11, 2021 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Aurora Acquisition Corp. ("Aurora" or the "Company") (NASDAQ:SRNG) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which Aurora, a special purpose acquisition company, will combine with Ginkgo Bioworks, Inc.
Business combination with Soaring Eagle Acquisition Corp. (Nasdaq:SRNG) values Ginkgo Bioworks, Inc. at a $15 billion pre-money equity valuation and is expected to provide up to $2.5 billion of primary proceeds.
Soaring Eagle Acquisition Corp. (the "Company"), the seventh public acquisition vehicle led by Eagle Equity Partners’ Harry Sloan, Jeff Sagansky and Eli Baker, today announced that holders of the units sold in the Company’s initial public offering of 172,500,000 units completed on February 26, 2021 (the "offering") may elect to separately trade the Class A ordinary shares and warrants included in the units commencing on or about April 19, 2021. Any units not separated will continue to trade on the Nasdaq Capital Market (the "Nasdaq") under the symbol "SRNGU," and each of the Class A ordinary shares and warrants will separately trade on the Nasdaq under the symbols "SRNG" and "SRNGW," respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and warrants.